Shots:
- Formycon & Lotus have reported the conclusion of their exclusive license agreement for Formycon’s FYB206, a biosimilar version of Keytruda (Pembrolizumab), in the APAC market
- Upon closing, Formycon will receive an upfront payment, plus potential development & regulatory milestone payments, & a share of gross profits after launch, while retaining responsibility for manufacturing & supplying the finished product
- FYB206 is nearing completion of clinical development, with 1EP data expected in Q1’26, after which Formycon & Lotus will coordinate preparation of regulatory submissions across APAC markets in line with local requirements
Ref: Lotus | Image: Lotus & Formycon | Press Release
Related News: Formycon Receives the US FDA Approval for Nufymco (Biosimilars, Lucentis)
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
